Feb 12 (Reuters) - CSL Ltd (CSL) :
- TOP-LINE RESULTS FROM PHASE 3 AEGIS-II TRIAL EVALUATING EFFICACY AND SAFETY OF CSL112
- THERE WERE NO MAJOR SAFETY OR TOLERABILITY CONCERNS WITH CSL112
- STUDY DID NOT MEET ITS PRIMARY EFFICACY ENDPOINT OF MACE REDUCTION AT 90 DAYS
News: CSL CSL Says Top-Line Results From Phase 3 Aegis-II Trial Evaluating Efficacy And Safety Of...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$264.13 |
Change
8.820(3.45%) |
Mkt cap ! $127.6B | |||
| Open | High | Low | Value | Volume |
| $258.12 | $264.81 | $257.91 | $191.1M | 728.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 97 | $264.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $264.14 | 15 | 4 |
View Market Depth
| Last trade - 14.36pm 22/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |